{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T08:07:28Z","timestamp":1648714048763},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T00:00:00Z","timestamp":1481155200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s00393-016-0242-8","type":"journal-article","created":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T02:21:44Z","timestamp":1481163704000},"page":"21-26","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ausschleichen und Beenden von immunsuppressiven Therapien bei Spondyloarthritiden (einschlie\u00dflich Psoriasisarthritis)"],"prefix":"10.1007","volume":"76","author":[{"given":"G.","family":"Scholz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,8]]},"reference":[{"key":"242_CR1","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","volume":"44","author":"JJ Anderson","year":"2001","unstructured":"Anderson JJ, Baron G, Van Der Heijde D et al (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44:1876\u20131886","journal-title":"Arthritis Rheum"},{"key":"242_CR2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/annrheumdis-2013-204229","volume":"74","author":"EG Araujo","year":"2015","unstructured":"Araujo EG, Finzel S, Englbrecht M et al (2015) High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission. Ann Rheum Dis 74:655\u2013660","journal-title":"Ann Rheum Dis"},{"key":"242_CR3","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","volume":"7","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Listing J, Brandt J et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7:R439\u2013444","journal-title":"Arthritis Res Ther"},{"key":"242_CR4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, Van Den Berg R, Baraliakos X et\u00a0al (2011) 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70:896\u2013904","journal-title":"Ann Rheum Dis"},{"key":"242_CR5","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H et\u00a0al (1994) A\u00a0new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J\u00a0Rheumatol 21:2281\u20132285","journal-title":"J Rheumatol"},{"key":"242_CR6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a\u00a0proposed objective target for treatment. Ann Rheum Dis 69:48\u201353","journal-title":"Ann Rheum Dis"},{"key":"242_CR7","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates LC, Moverley AR, Mcparland L et al (2015) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a\u00a0UK multicentre, open-label, randomised controlled trial. Lancet 386:2489\u20132498","journal-title":"Lancet"},{"key":"242_CR8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U (1978) Severe psoriasis \u2013 oral therapy with a\u00a0new retinoid. Dermatologica 157:238\u2013244","journal-title":"Dermatologica"},{"key":"242_CR9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG et\u00a0al (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137\u2013145","journal-title":"Arthritis Rheum"},{"key":"242_CR10","first-page":"789","volume":"9","author":"JF Fries","year":"1982","unstructured":"Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J\u00a0Rheumatol 9:789\u2013793","journal-title":"J Rheumatol"},{"key":"242_CR11","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG et\u00a0al (1994) A\u00a0new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J\u00a0Rheumatol 21:2286\u20132291","journal-title":"J Rheumatol"},{"key":"242_CR12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S et\u00a0al (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:499\u2013510","journal-title":"Ann Rheum Dis"},{"key":"242_CR13","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","volume":"51","author":"GH Kingsley","year":"2012","unstructured":"Kingsley GH, Kowalczyk A, Taylor H et al (2012) A\u00a0randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 51:1368\u20131377","journal-title":"Rheumatology (Oxford)"},{"key":"242_CR14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/00365521.2014.966753","volume":"50","author":"CL Kvasnovsky","year":"2015","unstructured":"Kvasnovsky CL, Aujla U, Bjarnason I (2015) Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. Scand J Gastroenterol 50:255\u2013263","journal-title":"Scand J Gastroenterol"},{"key":"242_CR15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s003930170033","volume":"60","author":"T Langenegger","year":"2001","unstructured":"Langenegger T, Fransen J, Forster A et\u00a0al (2001) Clinical quality management in rheumatoid arthritis. Z Rheumatol 60:333\u2013341","journal-title":"Z Rheumatol"},{"issue":"Suppl 11","key":"242_CR16","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/acr.20577","volume":"63","author":"PJ Mease","year":"2011","unstructured":"Mease PJ (2011) Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken) 63(Suppl 11):S64\u2013S85","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"242_CR17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00535-016-1191-3","volume":"51","author":"JO Musci","year":"2016","unstructured":"Musci JO, Cornish JS, Dabritz J (2016) Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases. J\u00a0Gastroenterol 51:531\u2013547","journal-title":"J Gastroenterol"},{"key":"242_CR18","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","volume":"55","author":"V Navarro-Compan","year":"2016","unstructured":"Navarro-Compan V, Plasencia-Rodriguez C, De Miguel E et al (2016) Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a\u00a0systematic literature review. Rheumatology (Oxford) 55:1188\u20131194","journal-title":"Rheumatology (Oxford)"},{"key":"242_CR19","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3899\/jrheum.141128","volume":"42","author":"C Plasencia","year":"2015","unstructured":"Plasencia C, Kneepkens EL, Wolbink G et\u00a0al (2015) Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity. J\u00a0Rheumatol 42:1638\u20131646","journal-title":"J Rheumatol"},{"key":"242_CR20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.berh.2014.10.005","volume":"28","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy D, Gensler LS (2014) Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol 28:807\u2013818","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"242_CR21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.reuma.2011.06.005","volume":"7","author":"JM Senabre-Gallego","year":"2011","unstructured":"Senabre-Gallego JM, Rosas-Gomez De Salazar J, Santos-Soler G et al (2011) Duration of treatment with etanercept and motives for discontinuation in a\u00a0cohort of patients with rheumatic disease. Reumatol Clin 7:385\u2013388","journal-title":"Reumatol Clin"},{"key":"242_CR22","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/annrheumdis-2013-203460","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper J, Lenaerts J, Wollenhaupt J et al (2014) Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a\u00a06-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis 73:108\u2013113","journal-title":"Ann Rheum Dis"},{"key":"242_CR23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Braun J, Dougados M et\u00a0al (2014) Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 73:6\u201316","journal-title":"Ann Rheum Dis"},{"key":"242_CR24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1136\/ard.2007.074724","volume":"67","author":"D Der Heijde Van","year":"2008","unstructured":"Van Der Heijde D, Landewe R, Feldtkeller E (2008) Proposal of a\u00a0linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2\u2011step and 10-step definitions. Ann Rheum Dis 67:489\u2013493","journal-title":"Ann Rheum Dis"},{"key":"242_CR25","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","volume":"68","author":"D Der Heijde Van","year":"2009","unstructured":"Van Der Heijde D, Lie E, Kvien TK et al (2009) ASDAS, a\u00a0highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811\u20131818","journal-title":"Ann Rheum Dis"},{"key":"242_CR26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/annrheumdis-2014-205202","volume":"75","author":"J Zavada","year":"2016","unstructured":"Zavada J, Uher M, Sisol K et al (2016) A\u00a0tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a\u00a0propensity score-matched cohort study. Ann Rheum Dis 75:96\u2013102","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-016-0242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-016-0242-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-016-0242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T01:29:02Z","timestamp":1498354142000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-016-0242-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,8]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["242"],"URL":"https:\/\/doi.org\/10.1007\/s00393-016-0242-8","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,8]]}}}